https://cancerbiologyprogram.med.wayne.edu/pdfs/hallmarks_cancer_article.pdf

Hallmarks of cancer: the next generation.

抗原变异可使得多种致病微生物易于逃避宿主免疫应答。表达在感染红细胞表面的恶性疟原虫红细胞表面蛋白1（PfPMP1）与感染红细胞、内皮细胞、树突状细胞以及胎盘的单个或多个受体作用，在黏附及免疫逃避中起关键的作用。每个单倍体基因组var基因家族编码约60种成员，通过启动转录不同的var基因变异体为抗原变异提供了分子基础。

疟原虫var基因转换速率变化导致抗原变异[英]／Paul H, Robert P, Christodoulou Z, et al//Proc Natl Acad Sci U S A

https://staff.blog.ui.ac.id/hsuryadi/files/2012/02/ROS_RNS.pdf

Free radicals and antioxidants in normal physiological functions and human disease

Pathogen Recognition and Innate Immunity

Several reactive oxygen species (ROS) are continuously produced in plants as byproducts of aerobic metabolism. Depending on the nature of the ROS species, some are highly toxic and rapidly detoxified by various cellular enzymatic and nonenzymatic mechanisms. Whereas plants are surfeited with mechanisms to combat increased ROS levels during abiotic stress conditions, in other circumstances plants appear to purposefully generate ROS as signaling molecules to control various processes including pathogen defense, programmed cell death, and stomatal behavior. This review describes the mechanisms of ROS generation and removal in plants during development and under biotic and abiotic stress conditions. New insights into the complexity and roles that ROS play in plants have come from genetic analyses of ROS detoxifying and signaling mutants. Considering recent ROS-induced genome-wide expression analyses, the possible functions and mechanisms for ROS sensing and signaling in plants are compared with those in animals and yeast.

REACTIVE OXYGEN SPECIES: Metabolism, Oxidative Stress, and Signal Transduction

Insulin inhibits gluconeogenesis and stimulates glucose conversion to glycogen and lipids. How these activities are coordinated to prevent hypoglycemia and hepatosteatosis is not clear. Fructose-1,6 bisphosphatase (FBP1) is rate controlling for gluconeogenesis. However, inborn human FBP1 deficiency does not cause hypoglycemia unless accompanied by fasting or starvation, which also trigger paradoxical hepatomegaly, hepatosteatosis, and hyperlipidemia in affected individuals. Hepatocyte FBP1-ablated mice exhibit identical fasting-conditional pathologies along with AKT hyperactivation, whose inhibition reversed hepatomegaly, hepatosteatosis and hyperlipidemia but not hypoglycemia. Surprisingly, fasting-mediated AKT hyperactivation is insulin-dependent. FBP1 prevents insulin hyperresponsiveness, independently of its catalytic activity, by interacting with AKT, PP2A-C and Aldolase-B (ALDOB) to specifically accelerate AKT dephosphorylation. Enhanced by fasting and weakened by elevated insulin, FBP1:AKT:PP2A-C:ALDOB complex formation, which is disrupted by human FBP1 deficiency mutations or a C-terminal FBP1 truncation, prevents insulin-triggered liver pathologies and maintains lipid and glucose homeostasis. Conversely, a complex disrupting peptide reverses diet-induced insulin resistance.

/pdf/fbp1-is-a-nonenzymatic-safety-valve-that-curtails-akt-26ewv37o.pdf

FBP1 is a nonenzymatic safety valve that curtails AKT activation to prevent insulin hyperresponsiveness

The present invention provides methods and compositions for the inhibition of B-cell maturation and antibody production without interfering with innate or T-cell mediated immunity.

Inhibition of B-cell maturation and antibody production

The invention provides methods for reducing growth and/or metastasis of androgen-independent (castration resistant) prostate cancer in a tissue in an animal. In one embodiment the method comprises administering to the animal a therapeutically effective amount of a compound that reduces the number of B cells, and/or the function of B cells, in the tissue. In yet another embodiment, the invention provides methods for reducing androgen-induced growth of prostate epithelial cells in prostate tissue in an animal. In one embodiment, the method comprises administering to the animal a therapeutically effective amount of a compound that reduces the number of B cells, and/or the function of B cells, in the tissue.

Methods for treating castration resistant prostate cancer and metastasis by reducing B-cell number and/or function

Tu1374: THERAPIES TARGETING MAST CELLS ARE EFFECTIVE IN IBS TREATMENT: A SYSTEMATIC REVIEW AND META-ANALYSIS

The present invention relates to compositions and methods for cancer diagnosis, treatment and drug screening. In particular, the present invention provides compositions and methods for targeting the nuclear translocation of IkB kinase-α (IKKα) and the IKKα-mediated suppression of Maspin expression observed in metastatic prostate cancer cells.

Michael Karin

Papers

FBP1 is a nonenzymatic safety valve that curtails AKT activation to prevent insulin hyperresponsiveness

Inhibition of B-cell maturation and antibody production

Methods for treating castration resistant prostate cancer and metastasis by reducing B-cell number and/or function

Tu1374: THERAPIES TARGETING MAST CELLS ARE EFFECTIVE IN IBS TREATMENT: A SYSTEMATIC REVIEW AND META-ANALYSIS

Method for detecting the presence of prostate cancer